Arcutis wins label expansion for younger use of psoriasis cream Zoryve

More than a year af­ter it was ap­proved for adults and chil­dren 12 years and old­er, Ar­cutis Bio­ther­a­peu­tics’ steroid-free top­i­cal cream for plaque pso­ri­a­sis is now avail­able for younger kids.

The FDA has ap­proved Zo­ryve (rof­lu­mi­last) for chil­dren as young as 6, Ar­cutis an­nounced Fri­day. The com­pa­ny test­ed Zo­ryve specif­i­cal­ly in skin folds for this pop­u­la­tion, where pso­ri­a­sis is more like­ly to oc­cur com­pared with adults. Ar­cutis touts the drug as a non-greasy, fast-ab­sorb­ing — and im­por­tant­ly, steroid-free — op­tion for young kids.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.